Functional Studies of CCAAT/Enhancer Binding Protein Site Located Downstream of the Transcriptional Start Site.

Yujie Liu  
*Drexel University College of Medicine*

Michael R. Nonnemacher  
*Drexel University College of Medicine*

Aikaterini Alexaki  
*Drexel University College of Medicine*

Vanessa Pirrone  
*Drexel University College of Medicine*

Anupam Banerjee  
*Drexel University College of Medicine*

Follow this and additional works at: [https://jdc.jefferson.edu/kimmelgrandrounds](https://jdc.jefferson.edu/kimmelgrandrounds)

Let us know how access to this document benefits you

*See next page for additional authors*

**Recommended Citation**

Liu, Yujie; Nonnemacher, Michael R.; Alexaki, Aikaterini; Pirrone, Vanessa; Banerjee, Anupam; Li, Luna; Kilareski, Evelyn; and Wigdahl, Brian, "Functional Studies of CCAAT/Enhancer Binding Protein Site Located Downstream of the Transcriptional Start Site." (2017). *Kimmel Cancer Center Papers, Presentations, and Grand Rounds*. Paper 60.

[https://jdc.jefferson.edu/kimmelgrandrounds/60](https://jdc.jefferson.edu/kimmelgrandrounds/60)
Functional Studies of CCAAT/Enhancer Binding Protein Site Located Downstream of the Transcriptional Start Site

Yujie Liu1, Michael R Nonnemacher1, Aikaterini Alexaki1, Vanessa Pirrone1, Anupam Banerjee1, Luna Li1, Evelyn Kilareski1 and Brian Wigdahl1,2

1Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA. 2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

ABSTRACT: Previous studies have identified a CCAAT/enhancer binding protein (C/EBP) site located downstream of the transcriptional start site (DS3). The role of the DS3 element with respect to HIV-1 transactivation by Tat and viral replication has not been characterized. We have demonstrated that DS3 was a functional C/EBPβ binding site and mutation of this site to the C/EBPβ knockout DS3-9C variant showed lower HIV-1 long terminal repeat (LTR) transactivation by C/EBPβ. However, it was able to exhibit similar or even higher transcription levels by Tat compared to the parental LTR. C/EBPβ and Tat together further enhanced the transcription level of the parental LAI-LTR and DS3-9C LTR, with higher levels in the DS3-9C LTR. HIV molecular clone viruses carrying the DS3-9C variant LTR demonstrated a decreased replication capacity and delayed rate of replication. These results suggest that DS3 plays a role in virus transcriptional initiation and provides new insight into C/EBP regulation of HIV-1.

KEYWORDS: HIV-1, C/EBP, Tat, transcription

Introduction

Human immunodeficiency virus type 1 (HIV-1) gene expression in cells of the monocyte–macrophage lineage has been shown to be critically dependent on the regulation of the long terminal repeat (LTR), the promoter that drives proviral gene expression from the integrated viral DNA template. In turn, LTR activation requires cellular transcription factors, such as nuclear factor-κB (NF-κB), CCAAT/enhancer binding protein (C/EBP), Sp1, and activating transcription factor/cyclic AMP response element binding protein (ATF/CREB), and a number of other transcription factors as previously reviewed.1–3 Tat has been shown to regulate the activity of HIV-1 LTR by interacting with its partner, cyclin T1.26,27 p-TEF is responsible for phosphorylation of the C-terminal domain of RNA polymerase II (RNA Pol II) and promotes transcription elongation.28,29 Tat was able to regulate the activity of HIV-1 LTR by interacting with a number of proteins, including Sp1, NF-κB, C/EBPβ, and CBP/p300.30–35 Specifically, Tat directly binds to C/EBPβ and is reported to regulate HIV-1 transcription as previously reviewed.22–25 Tat has been shown to be composed of at least six different proteins (C/EBP-α, β, γ, δ, ε, and ζ) and belongs to the basic leucine zipper transcription factor family.11 C/EBPβ has been reported to regulate HIV-1 transcription in different cell types in association with a number of cellular factors including Sp1, NF-κB, ATF/CREB, and CBP/p300 and the viral proteins, such as Tat and Vpr.6,12–21
in vitro and in vivo through amino acid residues 47–67. Furthermore, Tat expression in HeLa cells has been shown to lead to a significant increase in the nuclear levels of C/EBPβ and a corresponding increase in C/EBPβ DNA-binding activity to the IL-6 promoter. More recently, co-expression of Tat and C/EBPβ has been shown to enhance C/EBPβ binding to the HIV-1 LTR and modulate monocyte chemoattractant protein 1 (MCP-1) gene transcription in astrocytes. Based on the critical role of MCP-1 in monocytes infiltration to the site of injury or inflammation in the brain and a corresponding increase in C/EBPβ, HIV-1 LTR and Tat may be important in HIV-1 infection, especially in the development of HAD.

Recent studies have shown that the C/EBP-DS3 was able to regulate HIV-1 basal transcription level in U-937 cells, and the HIV-1 LTR containing a DS3 knockout phenotype (DS3-9C) exhibited a reduced level of HIV-1 basal transcription. Other transcription factor binding sites identified downstream of the HIV-1 transcriptional start sites, including binding sites for AP-1 (I, II, III), AP3-like (AP3-L), and Sp1, have been shown to regulate HIV-1 transcription and replication. Given the importance of the upstream C/EBP binding sites in HIV-1 replication in cells of the monocyte–macrophage lineage, the function of this newly identified downstream C/EBP binding site (C/EBP-DS3) was examined in this study. The studies reported herein indicate that the downstream C/EBP binding site was a functional C/EBP binding site. Transactivation of the HIV-1 LTR by C/EBPβ was inhibited when the LTR contained the DS3-9C variant. When C/EBPβ and Tat were expressed at increased concentrations, the response of the LTR depended on the concentration of each protein. If there were limited Tat and increasing levels of C/EBPβ, then loss of binding to DS3 due to the 9C variant demonstrated a decreased ability to transactivate the LTR. However, when C/EBPβ was limited with increasing amounts of Tat, the loss of binding at DS3 due to the 9C variation demonstrated an increased ability to transactivate the LTR. HIV-1 replication in U-937 monocytes showed a delay in replication at early time points most likely due to low levels of C/EBPβ and Tat and recovery of virus replication toward levels generated by the parental virus at later time points when there would be increased levels of Tat. Overall, DS3 plays a critical role in initiating HIV-1 subtype B transcription and replication.

**Materials and methods**

**Cell culture and cell treatments**

The U-937 human monocytic cell line (American Type Culture Collection, ATCC, CRL-1593.2) was grown in Roswell Park Memorial Institute medium (RPMI)-1640 media (Cellgro). Media was supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone), antibiotics, (penicillin, 100 U/mL, and streptomycin, 100 µg/mL; Cellgro), glucose (4.5 g/L, Cellgro), sodium pyruvate (1 mM, Cellgro), and HEPES (10 mM, Cellgro). 293T cells were maintained in Dulbecco's Modified Eagle Medium (ATCC) supplemented with FBS (10%), glucose solution (10%), sodium bicarbonate (2%), and antibiotics (penicillin and streptomycin at 40 µg/mL each). The cells were maintained at 37°C with 5% CO₂.

**Cloning and site-directed mutagenesis**

The LTR-containing DNA fragment (approximately 640 bp) was derived from the LAI molecular clone of HIV-1. The HIV-1 LAI-LTR was PCR amplified using the forward primer: 5'-GGGTTAAGACTGGAAGGCTAATTCACTCCC-3' and reverse primer: 5'-TCCCCGCGGT TAGAGATTTTCCACA-3' (Integrated DNA Technologies). The small nucleotide indicates the restriction endonuclease binding sites used for cloning. The amplified product was digested with KpnI and Sma I (Promega, Madison, WI) and ligated into a modified pGEM3- Basic vector, which contains the firefly luciferase (Luc) gene (Promega), to construct the parental LAI-LTR-Luc expression construct. The parental construct was used as a template for site-directed mutagenesis using the QuickChange mutagenesis procedure as described by the manufacturer (Stratagene) to construct the mutant construct LAI-DS3-9C- Luc. The following primers were used for site-directed mutagenesis, and the nucleotide that was mutated is underlined.

Cloning and site-directed mutagenesis

| Forward Primer | Reverse Primer |
|----------------|----------------|
| 5'-CATGGAGTGCCAAAAGGATCCTACTA-3' | 5'-TTAGATTTTCCACA-3' |

The italicized nucleotides in the forward primer correspond to sequence necessary for directional cloning into the pC/DNA3.1 TOPO vector (Invitrogen), while the underlined portion corresponds to the respective start site of translation. The amplified C/EBPβ PCR product was ligated into the pcDNA3.1 TOPO vector as described by the manufacturer (Invitrogen). The plasmid was verified by sequencing. To confirm proper protein expression, 30 µg of the C/EBPβ construct was transiently transfected into 3.0 × 10⁹ 293 F cells using 293fectin as described by the manufacturer (Invitrogen), and the cell nuclear extract was harvested for further analyses.
48 hours posttransfection. Western immunoblot analysis was performed with the nuclear extract using antibody specific for C/EBPβ (C/EBPβ, sc-150, Santa Cruz Biotechnology Inc.) for detection of a 45-kD protein. Electrophoretic mobility shift supershift analyses were performed to identify the specific proteins involved in DNA–protein complex formation (data not shown).

**Transient transfection analyses**

Exponentially growing U-937 cells were seeded at $1 \times 10^6$ cells in 2 mL of growth medium in 6-well plates on the day of transfection. Fugene6 transfection reagent was utilized in the transient transfection as described by the manufacturer (Roche). Briefly, 1 µg LAI-LTR-luciferase (LAI-LTR-Luc reporter construct or LAI-LTR containing the DS3-9C variant (LTR-DS3-9C-Luc) and 50 ng pRL-TK Renilla luciferase internal control (Promega) were transfected together or cotransfected with other expression vectors: pcDNA3.1-luciferase internal control (Promega) were transfected together. Luciferase activity was assayed using the dual luciferase assay system as described by the manufacturer (Promega). Normalization to renilla activity was performed with the nuclear extract using antibody specific for C/EBPβ (C/EBPβ, sc-150, Santa Cruz Biotechnology Inc.) C/EBPβ, sc-150, Santa Cruz Biotechnology Inc.) C/EBPβ or cotransfected with other expression vectors: pcDNA3.1-luciferase internal control (Promega) were transfected together

**Statistical analysis**

The results were statistically analyzed by Student's $t$-test. Differences between groups were considered significant if $P < 0.05$ was obtained.

**Results**

C/EBP-DS3 affects HIV-1 LTR transcription activated by C/EBPβ in U-937 cells

Although U-937 cells represent a promonocytic cell line, undifferentiated U-937 cells are exclusively susceptible to infection by CXCR4-utilizing (X4) HIV-1 strains and have been utilized in a number of HIV-1 replication studies to examine selected aspects of the viral life cycle. In particular, U-937 cells and X4 HIV-1 strains have been previously utilized for identifying upstream C/EBP binding sites required for HIV-1 replication in cells of the monocyte–macrophage lineage. Moreover, electrophoretic mobility shift analyses have shown that HIV-1 C/EBP-DS3 is able to form a
DNA–protein complex containing C/EBPβ protein from U-937 cell nuclear extract. Therefore, the role of C/EBP-DS3 in HIV-1 transcription was first investigated in U-937 promonocytic cells.

U-937 promonocytic cells were transfected with 1 µg parental HIV-1 LAI-LTR-Luc or the LAI-DS3-9C-Luc in the absence or presence of increasing amounts of C/EBPβ, as indicated in the figures. Western immunoblot assays were performed to demonstrate that the protein expression levels of C/EBPβ were increased in a dose-dependent manner when cotransfected with parental LTR or LTR-DS3-9C (Figure 1C). Expression of increasing amounts of C/EBPβ-2 (from 150, 300, 600 to 1200 ng per reaction) led to a dose-dependent increase in HIV-1 LTR activity in both the parental and DS3-9C LTR, with the parental LTR demonstrating a 2- to 5-fold higher level of activity (Figure 1). Specifically, in the presence of 1200 ng of C/EBPβ expression vector, when comparing to fold over the parental LTR basal activity, the maximal transactivation levels of parental LTR and LTR-DS3-9C were 2- to 5-fold higher, respectively (Figure 1A). When the results were analyzed as fold over their own basal activity, the transactivation levels were 5.5- and 3.3-fold, respectively (Figure 1B). These results indicated that, similar to the upstream C/EBP binding sites, C/EBP-DS3 was able to affect HIV-1 transcription through interaction with C/EBPβ. Specifically, the reduced occupancy of DS3 resulted in reduced ability to be transactivated by C/EBPβ.

Figure 1. DS3-9C exhibited reduced ability to be transactivated by C/EBPβ. U-937 cells were transiently transfected with 1 µg LAI-LTR-Luc or LAI-DS3-9C-Luc in the absence or presence of increasing amounts of C/EBPβ, as indicated in the figures. Twenty-four hours posttransfection, cell lysates were harvested and luciferase activity was measured. (A) Results were analyzed by comparing the fold over the parental basal LTR activity level. (B) Results were analyzed by comparing the fold over its own basal LTR activity level. Asterisk indicates that P value < 0.001. (C) The protein expression levels of C/EBPβ as demonstrated by Western blot were increased with the increasing amounts of C/EBPβ expression vectors cotransfected with LAI-LTR-Luc (upper) or LTR-DS3-9C-Luc (lower) in U-937 cells.

Tat activates the LTR-DS3-9C variant in U-937 monocytic cells

Previous studies have shown that some transcription factor binding sites located downstream of the HIV-1 transcriptional start site play an important role in the Tat-mediated transactivation of the HIV-1 LTR. To determine whether C/EBP-DS3 could also affect Tat transactivation of the LTR, U-937 cells were transfected with 1 µg parental LAI-LTR-Luc or LTR-DS3-9C-Luc reporter vectors in the absence or presence of increasing amounts of Tat. As shown in Figure 2, Tat expression increased the activity of both the parental and DS3-9C-containing LTRs. In the presence of 50 ng of Tat expression vector, the activity of the HIV-1 LTR was similar between the parental and DS3-9C-containing configurations, with elevated activities of 13.8- and 14.2-fold, respectively. In the presence of increasing amounts of Tat expression vectors from 150, 300 to 600 ng, both LTRs exhibited increased activity in a dose-dependent manner. Specifically, the parental LTR transactivation levels were increased up to 20-, 29.6-, and 35.7-fold, respectively, which was higher than the levels of LTR-DS3-9C, 16.7-, 19.7-, and 24.7-fold, respectively (Figure 2A). However, when 1200 ng Tat expression vector was added to the cells, the transactivation level of LTR-DS3-9C (38.9-fold) was similar to that of parental level (36.4-fold). These results indicated that the LTR-DS3-9C variant needed much higher concentrations of Tat to be activated to levels similar to parental LTRs when there were low levels of C/EBPβ present (similar to those detected in U-937 cells). When analyzing the results
obtained with the parental and LTR-DS3-9C variant by comparing each LTR to its own basal transcription level, increasing Tat expression increased the transcription levels of DS3-9C-containing LTRs by 26.0-, 31.9-, 38.0-, 47.5-, and 74.3-fold, respectively, which were actually higher than the levels of the parental LTR, 13.8-, 20.0-, 29.6-, 35.7-, and 36.4-fold, respectively (Figure 2B). These results suggest that Tat can help overcome the loss of C/EBP-mediated LTR activation, at least under selected physiological conditions.

HIV-1 LTR activities are further elevated by C/EBPβ and Tat together

Since the LTR-DS3-9C variant exhibited a lower transactivation capability in the presence of Tat, and both factors have been shown to be important for HIV-1 gene expression in cells of monocyte–macrophage lineage, further investigations to determine whether there was a specific interaction between C/EBPβ, Tat, and the HIV-1 LTR-DS3 variant were performed. U-937 cells were transfected with 1 µg parental or LTR-DS3-9C in the absence or presence of 50 ng Tat expression vector and increasing amounts of C/EBPβ expression vector. As shown in Figure 3, the cooperative interaction between Tat and C/EBPβ-2 has been observed in both LTR configurations. In particular, when analyzed as fold over the parental basal LTR activity level (Figure 3A), increasing amounts of C/EBPβ-2 (100–1200 ng) increased the parental LTR from 26-, 26.3-, 43.0- to 41.3-fold, respectively, while the LTR activity of the LTR-DS3-9C variant were increased by 16.8-, 33.2-, 30.6-, and 16.0-fold, respectively. Unlike the parental LTR, with greater amounts of C/EBPβ-2 (600 and 1200 ng), the transcription level of LTR-DS3-9C was decreased. When analyzed as fold was over their own basal transcription activity (Figure 3B), the maximal transcription level of LTR-DS3-9C-driven transcription was obtained with 50 ng Tat and 300 ng C/EBPβ-2 (55.9-fold), which was higher than the highest level achieved with the parental LTR (43.0-fold). These results indicated that the LTR-DS3-9C variant exhibited a greater ability to be induced by Tat and C/EBPβ-2 together, once LTR-DS3-9C basal level was enhanced to the level of the parental LTR.

In contrast, when U-937 cells were transfected with 1 µg parental LAI-LTR-Luc or LAI-DS3-9C-Luc in the absence or presence of 100 ng C/EBPβ expression vector and a series of increasing amounts of Tat expression vectors, LTR activity was increased in both parental and DS3-9C-containing LTRs. The maximum activity of the parental LTR and the LTR-DS3-9C variant occurred with 100 ng C/EBPβ and 600 ng Tat expression vector, 37.7- and 50.2-fold, respectively. In addition, in all Tat levels examined, LTRs containing the DS3-9C configuration resulted in increased LTR activity over the parental LTR demonstrating that loss of C/EBP binding to DS3 can be overcome by increased expression of C/EBPβ (which can be found in the cells of the activated monocyte–macrophage lineage) and increased expression of Tat, leading one to conclude that DS3-9C may be involved in controlling HIV-1 replication in activated monocyte–macrophage environments.

DS3-9C decreases HIV-1 LAI replication in U-937 monocytic cells

To determine the effects of DS3 on HIV-1 replication, the DS3-9C variation was incorporated into an infectious molecular clone of the LAI strain of HIV-1. Molecular clone-derived viral particles were used to infect U-937 cell lines (Figure 4). Levels of p24 in the media were measured at 3, 6, 9, and 12 days postinfection. In U-937 cells, when compared with the parental LAI viral strain, the HIV-1 DS3-9C-containing
variant viruses resulted in lower replication levels at each time point examined. However, the maximal p24 level of parental virus was 213 ng/mL at 3 days postinfection, after which time lower levels of virus were observed. However, the replication levels of HIV-1 DS3-9C variant viruses continuously increased from day 3 (p24 level was 53 ng/mL) to day 12 (p24 level was 112 ng/mL) postinfection (Figure 4). Although the HIV-1 LAI strain, a CXCR4-utilizing virus, was examined in this study, it was able to effectively infect U-937 cells, which has also been demonstrated in other studies.51,52 Therefore, the comparison of the replication levels of these two viruses indicated that the DS3-9C variant exhibited a decreased replication ability at early time points but clearly has the ability to reach parental levels at later time points.

**Discussion**

Although numerous studies have investigated the important roles played by upstream cis-acting transcription factor binding sites and their cognate transcription factors regulating HIV-1 gene expression, relatively few studies have been reported concerning the transcription factor binding sites located downstream of the transcriptional start site of HIV-1 LTR. The sequence analyses have shown that some transcription factor binding sites located downstream of the transcriptional start site exhibit a high degree of sequence conservation by comparison to the subtype B consensus sequence.5 High sequence conservation may indicate the positive selection of these sites during the course of viral evolution within patients and across the infected patient population. For example, the downstream AP-1 binding sites within subtype B LTRs have been shown to be highly conserved genotypically and affect the basal and Tat transactivation ability of the HIV-1 LTR.43,50 Proviruses
containing mutations in three AP-1 binding sites abolished HIV-1 replication in peripheral blood mononuclear cells and T-lymphocyte cell lines. Therefore, to better understand the pathogenesis of HIV-1, a more thorough characterization of the HIV-1 LTR is required, including studies of the transcription factor binding sites located downstream of the transcriptional start site.

Cells of the monocyte–macrophage lineage are important for HIV-1 replication and long-term persistence of HIV-1. Unlike T-lymphocytes, cells of the monocyte–macrophage lineage infected with HIV-1 are resistant to the cytopathic effects of the virus and serve as a long-lived reservoir for HIV-1-persistent infection. Furthermore, the ability of macrophages to migrate into other tissues or to invade the brain is relative to a number of HIV-1-associated diseases, including HAD. Additionally, studies have shown that cells of monocytic origin are able to harbor latent HIV-1 provirus in all stages of the disease even in patients receiving successful highly active antiretroviral therapy, indicating that in addition to resting CD4+ T-cells, monocyte–macrophage are another potential latent virus reservoir, which may be able to continue to accumulate and harbor replication-competent HIV-1.

Results reported herein suggest that one downstream C/EBP site with low DNA binding affinity for C/EBPβ (DS3-9C) might be related to HIV-1 persistence and reactivation in cells of the monocyte–macrophage lineage.

HIV-1LTRs containing the DS3-9C configuration (a knockout configuration) exhibit relatively lower basal signal and C/EBPβ-mediated LTR activity (Figure 1), suggesting that DS3-9C could function as a negative regulatory element, to suppress HIV-1 transcription, especially at the beginning of infection when minimal viral protein has been produced yet, helping HIV-1 to evade the immune response by essentially increasing the energy of activation required to achieve the productive virus replication phase driven by high concentrations of Tat. However, once the infected cells are activated by proper extracellular stimuli or in the presence of enough Tat protein, LTR-DS3-9C could function at levels comparable to parental LTRs or even with higher LTR activity (Figures 2 and 3). Specifically, compared with parental LTR, although the activity levels of LTR-DS3-9C were lower at certain quantities of Tat (150, 300, and 600 ng), LTR-DS3-9C was able to be activated to the similar levels in the presence of 50 and 1200 ng Tat, respectively, indicating that (1) LTR-DS3-9C was able to respond rapidly to the low quantities of Tat, which could be important for HIV-1 transcription initiation, and (2) LTR-DS3-9C was able to act as transcription-competent LTR in the presence of large quantities of Tat. The results also suggested that once LTR-DS3-9C activation was initiated, which was approximated in the assays by analyzing the results as fold over their own basal level, the maximal activity level of LTR-DS3-9C activation by Tat (74.3-fold) was significantly higher than that of parental LTR (36.6-fold), suggesting that (3) LTR-DS3-9C exhibited a greater degree of Tat inducibility. Additionally, when the LTR-DS3-9C was activated by the small amounts of C/EBPβ, LTR-DS3-9C exhibited a higher level of transactivation in the presence of Tat (Figure 3C and D), which further confirmed LTR-DS3-9C as a transcription-competent variant. The replication results demonstrated that although the levels of DS3-9C variant viruses were lower than those of the parental virus during the first 12 days postinfection, the levels were continuously increased while those of parental viruses attained a maximal level at 3 days postinfection and then started to decline (Figure 4), suggesting that there may be a delay in virus replication. Taken together, these results suggest that this site is regulated by the cell activation state and produced viral proteins, especially, the amounts of C/EBPβ and Tat present within the infected cell.

HIV-1 infection in T-lymphocytes or cells of the monocyte–macrophages could result in three possible outcomes: (1) productive replication without efficient immune recognition leading to extensive viral production and the death of the host cells; (2) productive replication with immune recognition leading to the clearance of infected cells prior to high-level virus production; and (3) infection leading to limited viral gene expression and failure to eliminate infected cells by the immune system with continued maintenance of latent or persistent provirus within the infected cell population (Figure 5). Based on these observations, we propose that infection with virus containing the LTR-DS3-9C variant could lead to the third outcome. Specifically, during the early stage of HIV-1-DS3-9C infection, no Tat protein was produced and the transcription was totally dependent on host cell factors (NF-κB, Sp1, Sp2, and C/EBPβ).
C/EBPβ, CBP/p300, PCAF, etc.\textsuperscript{17,59–62} LTR-DS3-9C-containing viruses exhibited relatively low basal transcription and replication level, which helped DS3-9C viruses evade immune system surveillance and perhaps be retained in the infected cell population. With disease progression and/or some external stimuli, the infected cells were activated; the active form of NF-κB could be produced and translocated to the nucleus; and the expression levels of Sp1 and C/EBPβ were increased, all promoting HIV-1 transcription initiation. Subsequently, Tat was produced, and efficient transcription elongation occurred, allowing DS3-9C variant viruses to replicate with a delayed phenotype.

Recent studies have shown the linkage between HIV-1 replication and disease progression with genetic alterations in selected transcription factor binding sites within the HIV-1 LTR, such as Sp1-binding site\textsuperscript{63,64} and US1 C/EBP site.\textsuperscript{10} It is possible that virus containing the DS3-9C variant might be associated with a greater propensity to establish latency. Defective HIV-1 transcription, which could be caused by (1) low levels of NF-κB\textsuperscript{65–67} (2) low levels of Tat,\textsuperscript{68–72} and (3) limited cellular coactivators, such as cyclin T1, a component of the p-TEF complex,\textsuperscript{65,73} is one of the major reasons for HIV-1 latency. Although transient transfection provides a simpler chromatin structure, it helps in understanding activities of integrated LTRs. The establishment of an open nucleosome-1 critical for HIV-1 gene expression\textsuperscript{74,75} and DS3-9C is located at the 3′ edge of nucleosome-1 (nuc-1), so it is possible that DS3-9C variant may lead to a structural change in the LTR that results in a specific restrictive chromatin structure limiting the accessibility of Tat and coactivators (HAT and/or SWI/SNF) to the LTR, thereby resulting in a low level of HIV-1 transcription and possibly latency. Within the context of proper stimuli, the latent viruses are able to reactivate and function as parental viruses.

Conclusion

The function of one C/EBP binding site located downstream of the HIV-1 LTR transcription start site has been characterized. This binding site configuration with low DNA binding affinities for C/EBPβ (DS3-9C) may be transcriptionally competent and be able to facilitate productive replication in the presence of Tat. This LTR variant may promote HIV-1 persistence and reactivation in cells of the monocyte–macrophage lineage. Further experiments will examine the role of this interesting cis-acting element in vivo, utilizing stably integrated LTRs or genomes containing the DS3-9C variant in different cell types under an assortment of stimulatory conditions. With respect to the important roles played by upstream and downstream C/EBP binding sites in the regulation of HIV-1 gene expression in cells of the monocyte–macrophage lineage, C/EBP binding sites may be the potential targets for design of novel forms of HIV-1 therapeutics.

Acknowledgements

We would like to thank Kamel Khalili (Temple University, Philadelphia, PA) for providing the pcDNA3-Tat86 expression vector.

Author contributions

Conceived and designed the experiments: YL, MRN, AA, VP, AB, LL, EK, and BW. Analyzed the data: YL, MRN, VP, AB, EK, and BW. Wrote the first draft of the manuscript: YL. Contributed to the writing of the manuscript: YL, MRN, AA, VP, AB, LL, EK, and BW. Agreed with manuscript results and conclusions: YL, MRN, AA, VP, AB, LL, EK, and BW. Jointly developed the structure and arguments for the paper: YL, MRN, and BW. Made critical revisions and approved the final version: YL, MRN, AA, VP, AB, LL, EK, and BW. All the authors reviewed and approved the final manuscript.

REFERENCES

1. García JA, Gaynor RB. The human immunodeficiency virus type-1 long terminal repeat and its role in gene expression. Prog Nucleic Acid Res Mol Biol. 1994;49:157–196.
2. Krebs FC, Hogan TH, Quietero S, Gartner S, Wigdahl B. Lentiviral LTR-Directed Expression, Sequence Variation, and Disease Pathogenesis. Los Alamos, NM: National Laboratory HIV Sequence Compendium; 2001. https://www.hiv.lanl.gov/content/sequence/HIV/REVIEWS/WIGDAHL2001/Wigdahl.html.
3. Kingsman SM, Kingsman AJ. The regulation of human immunodeficiency virus type 1 gene expression. Eur J Biochem. 1996;240(3):491–507.
4. Tesmer VM, Rajadhyaksha A, Babin J, Bina M. NF-IL6-mediated transcriptional activation of the long terminal repeat of the human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1993;90(15):7289–7302.
5. Dayha S, Liu Y, Nonnemacher MR, Damper W, Wigdahl B. CCAAT enhancer binding protein and nuclear factor of activated T cells regulate HIV-1 LTR via a novel conserved downstream site in cells of the monocyte-macrophage lineage. PLoS One. 2014;9(2):e88116.
6. Henderson AJ, Connor RI, Calame KL. C/EBP activators are required for HIV-1 replication and proviral induction in monocyte cell lines. Immunity. 1996;5(1):91–101.
7. Henderson AJ, Zou X, Calame KL. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/mosteocytes. J Virol. 1995;69(9):5337–5344.
8. Ross HL, Nonnemacher MR, Hogan TH, et al. Interaction between CCAAT/ enhancer binding protein and cyclic AMP response element binding protein 1 regulates human immunodeficiency virus type 1 transcription in cells of the monocyte/macrophage lineage. J Virol. 2001;75(4):1842–1856.
9. Hogan TH, Krebs FC, Wigdahl B. Regulation of human immunodeficiency virus type 1 gene expression and pathogenesis by CCAAT/enhancer binding proteins in cells of the monocyte/macrophage lineage. J Neurovirol. 2002;8(suppl 2):21–26.
10. Hogan TH, Strauff DL, Krebs FC, Gartner S, Quietero SJ, Wigdahl B. Structural and functional evolution of human immunodeficiency virus type 1 long terminal repeat CCAAT/enhancer binding protein sites and their use as molecular markers for central nervous system disease progression. J Neurovirol. 2003;9(1):55–68.
11. Ramji DP, Foka P, CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365(pt 3):541–575.
12. Dumas N, Bounou S, Olivier M, Tremblay MJ. Prostaglandin E(2)-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5′-monophosphate response element binding protein. J Immunol. 2002;168(1):274–282.
13. Buckner AE, Tesmer VM, Bina M. Regulation of HIV-1 transcription by NF-IL6 in activated Jurkat T cells. Virus Res. 2002;89(1):53–63.
14. Tesmer VM, Bina M. Regulation of HIV-1 gene expression by NF-IL6. J Mol Biol. 1996;262(3):327–335.
18. Mink S, Haenig B, Klempnauer KH. Interaction and functional collaboration of Liu et al

21. Burdo TH, Nonnemacher M, Irish BP, et al. High-affinity interaction between

17. Lee ES, Sarma D, Zhou H, Henderson AJ. CCAAT/enhancer binding

20. Ruocco MR, Chen X, Ambrosino C, et al. Regulation of HIV-1 long terminal repeats by interaction of C/EBP(NF-IL-6) and NF-kappaB/Rel factors. J Biol Chem. 1996;271(37):22479–22486.

24. Gatignol A, Jeang KT. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Adv Pharmacol. 2000;48:209–227.

28. Chun RF, Jeang KT. Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1. J Biol Chem. 1996;271(44):27884–27890.

29. Yang X, Gold MO, Tang DN, et al. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A. 1997;94(23):12313–12316.

30. Loregian A, Bortolozzo K, Boso S, Caputo A, Palu G. Interaction of Sp1 transcription factor with HIV-1 Tat protein: looking for cellular partners. FEBS Lett. 2003;543(1–3):61–65.

31. Yadavilli VS, Benkirane M, Jeang KT. Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclophilin T-cell lymphotropic virus I and HIV-1. J Biol Chem. 1996;271(44):27884–27890.

32. Furia B, Deng L, Wu K, et al. Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and C/EBPbeta. Mol Cell Biochem. 1997;171(11):6609–6617.

35. Munkerje R, Sawaya BE, Khalili K, Amini S. Association of p65 and C/EBP with HIV-1 LTR modulators of viral transcription. J Cell Biochem. 2007;100(5):1210–1216.

36. Bertoft TH, Nonnemacher M, Irish BP, et al. High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-kappaB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol. 2004;23(4):261–269.

37. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem. 1999;274(41):28877–28840.

38. Chun RF, Jeang KT. Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1. J Biol Chem. 1996;271(44):27884–27890.

40. Mengozzi M, De Filippi C, Transidico P, et al. Human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol. 2006;80(5):1018–1030.

41. Roebuck KA, Gu DS, Kagnoff MF. Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression. AIDS. 1996;10(8):819–826.

42. Biswas P, Mengozzi M, Mantelli B, et al. 1,25-Dihydroxyvitamin D3 upregulates functional CXCXR4 human immunodeficiency virus type 1 co receptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication. J Virol. 1998;72(10):8380–8383.

43. Cassel E, Alfano M, Biassou P, Poli G. Monocyte-derived macrophages and myeloid cells as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006;80(5):1018–1030.

44. el Kharroubi A, Verdin E. Protein-DNA interactions within DNase I hypersensitive sites: HIV transactivation components, target binding sites downstream of the HIV-1 promoter. J Biol Chem. 1994;269(31):19916–19924.

45. Thavathiru E, Das GM. Activation of pRLL-TK by 125 I EA oncoprotein: drawbacks of using an internal reference reporter in transcription assays. Biotechniques. 2001;31(3):528–530,532.

46. Grant C, Nonnemacher M, Jain P, et al. CCAAT/enhancer-binding proteins modulate human T cell leukemia virus type 1 long terminal repeat activation. Virology. 2006;348(2):354–369.

47. Farr A, Roman A. A pitfall of using a second plasmid to determine transfection efficiencies. Nucleic Acid Res. 1992;20(9):2190.

48. Grant C, Jain P, Nonnemacher M, et al. AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocyte differentiation. J Leukoc Biol. 2006;80(3):640–650.

49. Cassel E, Alfano M, Biassou P, Poli G, et al. A family of serine proteases expressed exclusively in myeloid-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med. 1994;180(4):1445–1446.

50. Montaner LJ, Crowe SM, Aquaro S, Perno CF, Stevenson M, Collman RG. Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understanding areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol. 2006;80(5):961–964.

51. Biswas P, Mengozzi M, Mantelli B, et al. 1,25-Dihydroxyvitamin D3 upregulates functional CXCXR4 human immunodeficiency virus type 1 co receptors in U937 minus clones: NF-kappaB-independent enhancement of viral replication. J Virol. 1998;72(10):8380–8383.

52. Francioso G, Biassou P, Poli G, et al. A family of serine proteases expressed exclusively in myeloid-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med. 1994;180(4):1445–1446.

53.多种形式の細胞において共役される全般の血球を含むポリペプチドの解析を行い、AIDSに寄与する可能性を示す。J Virol. 2006;80(5):961–964.
63. Hiebenthal-Millow K, Greenough TC, Bertriller DB, et al. Alterations in HIV-1 LTR promoter activity during AIDS progression. *Virology*. 2003;317(1):109–118.

64. Ramírez de Arellano E, Martín C, Soriano V, Alcamí J, Holguín A. Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. *Virus Genes*. 2007;34(2):111–116.

65. Hennighausen L, Furtth PA. NF-kB and HIV. *Nature*. 1990;343(6255):218–219.

66. Williams SA, Chen LF, Kwon H, et al. Prostratin antagonizes HIV latency by activating NF-kappaB. *J Biol Chem*. 2004;279(40):42008–42017.

67. Williams SA, Kwon H, Chen LF, Greene WC. Sustained induction of NF-kappaB is required for efficient expression of latent human immunodeficiency virus type 1. *J Virol*. 2007;81(11):6043–6056.

68. Brady J, Kashanchi F. Tat gets the "green" light on transcription initiation. *Retrovirology*. 2005;2:69.

69. Marcello A, Zoppe M, Giacca M. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. *IUBMB Life*. 2001;53(3):175–181.

70. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. *EMBO J*. 2003;22(24):6550–6561.

71. Lin X, Irwin D, Kanazawa S, et al. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. *J Virol*. 2003;77(5):8227–8236.

72. Roebuck KA, Saiifuddin M. Regulation of HIV-1 transcription. *Gene Expr*. 1999;8(2):67–84.

73. Ghose R, Liou LY, Herrmann CH, Rice AP. Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. *J Virol*. 2001;75(23):11336–11343.

74. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. *EMBO J*. 1996;15(5):1112–1120.

75. El Kharroubi A, Piras G, Zensen R, Martin MA. Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. *Mol Cell Biol*. 1998;18(5):2535–2544.